Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21992707 | 0.87 | PPARA (0.54) | SMN1; SMN2LMNAKDM4EMAPTPPARA | |
| SCHEMBL11707662 | 0.86 | PPARA (0.52) | LMNAMAPTGAAPPARADRD2 | |
| SCHEMBL21991575 | 0.85 | CYP1A2 (0.45) | SMN1; SMN2LMNAFAAHKDM4EMAPT | |
| SCHEMBL21991339 | 0.85 | PPARA (0.55) | LMNAMAPTPPARAMEN1KMT2A | |
| SCHEMBL21991954 | 0.84 | ALDH1A1 (0.50) | SMN1; SMN2LMNAKDM4EMAPTPPARA | |
| SCHEMBL21991577 | 0.84 | PPARA (0.53) | SMN1; SMN2KDM4EMAPTSSTR4PPARA | |
| SCHEMBL21991531 | 0.84 | SSTR4 (0.53) | SMN1; SMN2LMNAFAAHMAPTGAA | |
| SCHEMBL21991976 | 0.84 | PPARA (0.59) | SMN1; SMN2LMNAKDM4EPPARA | |
| SCHEMBL21991337 | 0.84 | SMN1; SMN2 (0.43) | SMN1; SMN2LMNAFAAHKDM4ELTA4H | |
| SCHEMBL21992730 | 0.81 | PPARA (0.52) | LMNALTA4HPPARAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | SMN1; SMN2 3122/4885LMNA 4533/4885FAAH 1704/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | SMN1; SMN2 3122/4885LMNA 4533/4885FAAH 1704/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | SMN1; SMN2 3122/4885LMNA 4533/4885FAAH 1704/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | SMN1; SMN2 3122/4885LMNA 4533/4885FAAH 1704/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | SMN1; SMN2 3122/4885LMNA 4533/4885FAAH 1704/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | SMN1; SMN2 3122/4885LMNA 4533/4885FAAH 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.